Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
MIT News reports a two-stage process that measures lipid nanoparticle size during production and uses the resulting data to guide processing conditions for RNA-therapy development. The team is pursuing commercialisation through BIZON Labs; no clinical testing is reported.
GBI plans to introduce SmartScale, a service aimed at early-stage developers seeking GMP material for clinical development. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners will assess automated manufacture of GenomeFrontier's virus-free CAR T process; the collaboration is Cellares' first with an Asian cell-therapy developer. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →SynGenSys introduced an expanded synthetic promoter library designed for biomanufacturing applications in CHO cells. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →DNA Script reports an ARPA-H award for a DNA manufacturing effort that incorporates its enzymatic synthesis technology. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The NeX solution builds on Enzene's continuous manufacturing platform and is presented as a transportable biologics production option. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A new test bed linked to the University of Maryland and NIST will support programmable, automated manufacturing workflows. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaboration combines Constellation and autoloMATE to address fragmented manufacturing data and process visibility. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners plan to move manufacturing of SBT-77-7101 to Cellares' Cell Shuttle and evaluate automated quality-control testing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Shilpa has commissioned an integrated site for manufacturing antibody-drug conjugate drug substance under GMP conditions. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →An independent UK centre reports a continuous bioprocess intended to improve productivity and lower costs for advanced-therapy manufacturing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners will evaluate automated manufacturing for TScan's TSC-101 as that programme moves toward a planned pivotal study. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaboration covers production and quality control of a personalised progenitor T-cell therapy being developed for blood cancers. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaborators will examine how automation could make cell-therapy production more efficient and scalable. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies are moving a candidate toward GMP manufacturing after cell-line development, with technology transfer planned between sites. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The company's newly announced control system emphasises instrument integration and real-time manufacturing oversight. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reviews the translation of nonviral gene-delivery platforms, including lipid and polymer-based approaches. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The WHO designation focuses on workforce training and technology transfer as manufacturing capacity expands across regions. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Artis is bringing Syngoi Technologies to a US hub serving synthetic-DNA development and clinical manufacturing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Eveo is designed to bring cell selection, activation, gene modification and final formulation into one closed workflow. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →City of Hope and Cellares agreed to assess Cell Shuttle and Cell Q for solid-tumour CAR T manufacturing and quality control. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →EirGenix gained access to Transcenta's HiCB technologies, which include continuous perfusion and hybrid continuous purification. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A two-step microfluidics system created ternary nano-scale lipopolyplexes, using polymer choice to determine the lipopolyplexes’ structure, which affects vector size and distribution. This overcomes barriers to manufacturing and creates nonviral vectors for efficient DNA delivery. The post Microfluidics-Manufactured Lipopolyplexes Offer Size Consistency appeared first on GEN - Genetic Engineering The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A close partnership between academic institutions, industry, and the FDA is necessary for success in manufacturing personalised treatment. That’s a key message behind a talk at BPI this week, presented by Max Sellman of Aldevron. The post Collaboration Key to First Personalised mRNA-based CRISPR Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call
